Molecular profiling company Caris Life Sciences has entered a multi-year strategic collaboration with drug discovery company Flare Therapeutics to speed up precision medicine approaches across five of Flare's therapeutic programs. Flare plans to leverage Caris’ solutions in its clinical trials to guide patient selection and participation.
The collaboration will leverage Caris' molecular tissue and liquid profiling services, including whole-exome sequencing and whole-transcriptome sequencing for patients enrolled in Flare's clinical trials. Caris will also provide data insights and analytics capabilities to accelerate oncology drug discovery and identify novel biomarkers for Flare's pipeline. The partnership will allow Caris the first option to develop a companion diagnostic for any drug candidate developed as part of the collaboration.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.